Konopleva et al., 2002 - Google Patents
The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cellsKonopleva et al., 2002
- Document ID
- 7306827275699445431
- Author
- Konopleva M
- Zhao S
- Hu W
- Jiang S
- Snell V
- Weidner D
- Jackson C
- Zhang X
- Champlin R
- Estey E
- Reed J
- Andreeff M
- Publication year
- Publication venue
- British journal of haematology
External Links
Snippet
In acute myeloid leukaemia (AML), cell kinetic quiescence has been postulated to contribute to drug resistance. As the anti‐apoptotic genes Bcl‐2 and Bcl‐XL have been implicated in cell cycle regulation, we investigated the expression of these genes in non‐proliferating (Q) …
- 102100013894 BCL2 0 title abstract description 119
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Konopleva et al. | The anti‐apoptotic genes Bcl‐XL and Bcl‐2 are over‐expressed and contribute to chemoresistance of non‐proliferating leukaemic CD34+ cells | |
Tuomisto et al. | Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance | |
Ito et al. | Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis | |
Hormaechea-Agulla et al. | Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling | |
Konopleva et al. | Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins | |
Andreeff et al. | Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid | |
González‐Tablas Pimenta et al. | Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome | |
Osada et al. | The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients | |
Wu et al. | Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival | |
Gorczyca | Atlas of differential diagnosis in neoplastic hematopathology | |
Fraser et al. | Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone | |
Seiffert et al. | Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo | |
Strack et al. | Identification of tumor‐associated macrophage subsets that are associated with breast cancer prognosis | |
Mehmeti-Ajradini et al. | Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer | |
Reidel et al. | Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile | |
Ball et al. | CDDO-Me alters the tumor microenvironment in estrogen receptor negative breast cancer | |
Ravoet et al. | 6q-is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome | |
US20180059115A1 (en) | Methods for monitoring polymorphonuclear myeloid derived suppressor cells, and compositions and methods of treatment of cancer | |
Vanmeerbeek et al. | Targeting conserved TIM3+ VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy | |
da Silveira Júnior et al. | P‐glycoprotein and multidrug resistance‐associated protein‐1 expression in acute myeloid leukemia: Biological and prognosis implications | |
Teo et al. | Single-cell transcriptomics of peripheral blood in the aging mouse | |
Boiocchi et al. | Composite chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma are biclonal lymphomas: a report of two cases | |
Wen et al. | High throughput quantitative reverse transcription PCR assays revealing over‐expression of cancer testis antigen genes in multiple myeloma stem cell‐like side population cells | |
Chen et al. | Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment | |
Pallis et al. | Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p‐glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications |